PxRadia

PxRadia develops a humanized monoclonal antibody 2A2 for mitigating radiation toxicity and preventing cell death.

PxRadia was formed in 2010 by Dr. Charles Morgan, a founder of multiple companies and a pioneer in monoclonal antibody development, with an exclusive license from Memorial Sloan-Kettering Cancer Center to commercialize the breakthrough research of Dr. Richard N. Kolesnick on the role of ceramide, a lipid, in cell signaling and cell death.